Real-time PCR detection of 16S rRNA novel mutations associated with Helicobacter pylori Tetracycline resistance in Iran

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 20, 2014, Pages 8883-8886

  Dadashzadeh, Kianoosh ^a,b   Milani, Morteza ^b,c   Rahmati, Mohammad ^d   Akbarzadeh, Abolfazl ^e  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antimicrobial resistance mechanisms; DNA polymorphisms; Light cycler

Indexed keywords

RNA 16S;

ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMAN; IRAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; MUTATION; REAL TIME POLYMERASE CHAIN REACTION;

HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRAN; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; RNA, RIBOSOMAL, 16S; TETRACYCLINE RESISTANCE;

EID: 84911072476     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.20.8883     Document Type: Article

References (18)

1. Abrams DN, Koslowsky I, Matte G (2000). Pharmaceutical interference with the [1v4C] carbon urea breath test for the detection of Helicobacter pylori infection. J Pharm Pharm Sci, 3, 228-33
2. Anoushiravani M, Falsafi, T, Niknam V (2009. Proton motive force-dependent efflux of tetracycline in clinical isolates of Helicobacter pylori. J Med Microbiol, 58, 1309-3
3. Dailidiene D, Bertoli MT, Miciuleviciene J (2002). Emergence of tetracycline resistance in Helicobacter pylori: multiple mutational changes in 16S ribosomal DNA and other genetic loci. Antimicrob Agents Chemother, 46, 3940-6
4. De Francesco V, Giorgio F, Hassan C, et al (2010). Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis, 19, 409-14
5. Gerrits MM, De Zoete MR, Arents NL, Kuipers EJ, Kusters, JG (2002). 16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrobial Agents Chemotherapy, 46, 2996-3000
6. Gisbert JP, Pajares JM (2001). Helicobacter pylori therapy: first-line options and rescue regimen. Digestive Diseases, 19, 134-43
7. Glocker E, Berning M, Gerrits MM, Kusters JG, Kist M (2005). Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori. Antimicrobial Agents Chemotherapy, 49, 3166-70
8. Heep M, Kist M, Strobel S, Beck D, Lehn N (2000). Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis, 19, 538-41
9. Lawson A J, Elviss NC, Owen RJ (2005). Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales. Antimicrobial Agents Chemotherapy, 56, 282-6
10. Malekimsc P, Siavoshiphd F (2013). Helicobacter pylori vacA d1/-i1 Genotypes and Geographic Differ-entiation between High and Low Incidence Areas of Gastric Can-cer in Iran. Arch Iran med 16, 330
11. Malfertheiner P, Megraud F, O'morain C, et al (2007). Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut, 56, 772
12. Mansour-Ghanaei F, Joukar F, Soati F, Mansour-Ghanaei A, Atrkar-Roushan Z (2013). Outcome of intestinal metaplasia in gastric biopsy of patients with dyspepsia in Guilan Province, North Iran. Asian Pac J Cancer Prev, 14, 3549-54
13. Mcnulty C, Owen R, Tompkins D, et al (2002). Helicobacter pylori susceptibility testing by disc diffusion. J Antimicrobial Chemotherapy, 49, 601
14. Milani M, Ghotaslou R, Akhi MT, et al (2012). The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics. J Infect Chemother, 18, 848-52
15. Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L (2010). Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter, 15, 505-9
16. Wang Y, Zhang FC, Wang YJ (2014). Helicobacter pylori and pancreatic cancer risk: a meta-analysis based on 2,049 cases and 2,861 controls. Asian Pac J Cancer Prev, 15, 4449-54
17. Wu H, Shi X, Wang H, Liu J (2000). Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrobial Chemotherapy, 46, 121-3
18. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D (2012). Standard triple and sequential therapies for Helicobacter pylori eradication: An update. Eur J Int Med, 24, 16-9